Physician profile
Jazmyn Childress
NPI 1679281380
$7,060.28
in general payments reported to CMS, 2019-2025
18 companies · $3,315 in 2025
The $3,315 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Registered Nurse) providers received nationally (typical 2025 total: $137).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,185 · 2024: $2,560 · 2025: $3,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,937 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,936.92 |
| Education | $123.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,553.13 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $731.30 | 2024-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $676.60 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $627.51 | 2023-2025 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $621.26 | 2025 | Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $615.44 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $599.41 | 2023-2024 | Spravato, Invega Sustenna |
| Alkermes, INC. | $576.89 | 2024-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $288.17 | 2023-2024 | Auvelity, Sunosi |
| E.R. Squibb & Sons, L.L.C. | $277.69 | 2025 | Cobenfy |
| Almatica Pharma LLC | $162.89 | 2023-2025 | Loreev Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.08 | 2023-2025 | Xifaxan |
| Neurocrine Biosciences, INC. | $57.61 | 2025 | |
| Bausch Health US, LLC | $46.00 | 2024 | Aplenzin |
| Takeda Pharmaceuticals U.S.A., INC. | $45.03 | 2023 | Trintellix |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $23.50 | 2024 | Dyanavel Xr |
| Braeburn INC. | $19.77 | 2024 | Brixadi |
| Idorsia Pharmaceuticals US INC | $18.00 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jazmyn Childress listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.